Compare Merck & Co., Inc. (MRK) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Global X SuperDividend ETF — how do they compare? Merck & Co., Inc. trades at $142.16 (market cap $352.29B), while Global X SuperDividend ETF trades at $23.75 (market cap $1.17B). The key difference: Merck & Co., Inc. is far larger — about 301.1× Global X SuperDividend ETF's market cap, and Merck & Co., Inc. pays a 2.38% dividend while Global X SuperDividend ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Global X SuperDividend ETF for 47 Days on average.
| MRK | SDIV | |
|---|---|---|
Market Cap | $352.29B | $1.17B |
Volume | 6,348,796 | 432,039 |
Sector | Health | Broad Market / Factor |
52-Week High | $156.43 | $26.34 |
52-Week Low | $82.49 | $22.90 |
Typical Hold Time | 98 Days | 47 Days |
Enterprise Value | $399.05B | — |
Dividend Yield | 2.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $142.40, up 0.33% on the day, with a bearish technical signal but strong analyst support. The company reported revenue of $65.0B in 2025 with a net income margin of 28.07%, though 2026 projections show a sharp decline to 4.76%. Recent acquisition activity includes the tender offer for Terns Pharmaceuticals to bolster its oncology pipeline, while cash flow trends indicate significant investing outflows in 2026.
The outlook is mixed: robust fundamentals and a consensus price target of $159.59 suggest upside, but high valuation ratios (P/E 114.23) and projected earnings volatility pose risks. Investors should weigh strong institutional buying against technical weakness and competitive pressures in the pharma sector.
SDIV trades at $23.58, down 0.55% with a bearish technical signal from moving averages. The ETF maintains an 8%+ dividend yield but faces scrutiny over principal erosion, having lost 66% since inception. Recent institutional buying by Ameritas Advisory contrasts with negative media coverage questioning sustainability of high yields amid capital depreciation.
Outlook remains challenged by structural underperformance versus benchmarks. The high yield attracts income seekers but masks negative growth and volatility risks. Investment case hinges on yield sustainability versus capital preservation, with analyst sentiment cautious given persistent track record of value destruction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
